Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06475287 | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475911 | Impact of Peri-Operative Hyponatremia on Postoperative Outcomes in Major HPB Surgeries for Cancers | unknown | — | 500 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06428708 | [18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma | unknown | Early Phase 1 | 30 | Western UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06465030 | Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma | unknown | — | 35 | Sohag UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05444088 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 129 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06467565 | NALIRIFOX as Induction Therapy in LAPC | unknown | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06468696 | Improvements in Thyroid Tumor Surgery and the Prognosis, Diagnosis, Recurrence and Metastasis of Patients | unknown | N/A | 170 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02977468 | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer(Pembro/IORT) | unknown | Phase 1 | 15 | Eileen ConnollyOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06427993 | Urine DNA Methylation Detection for Hematuria Evaluation | unknown | — | 71 | Changhai HospitalOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06463171 | Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06372626 | Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | unknown | Phase 1 / Phase 2 | 93 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06458725 | Assessment of DW-MRI Measures : Reproducibility and Repeatability in Pelvic Imaging on MR-Linac With Healthy Volunteers(PILLAR) | unknown | N/A | 30 | Jules Bordet InstituteOTHER | 0 | Jun 14, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT05717738 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma(CCGLC-008) | unknown | — | 300 | Tongji HospitalOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06450080 | Study of the Relationship Between Clinical, Imaging and Biological Data in Patients With Squamous Cell Carcinoma of the Tongue(ClimaBio) | unknown | N/A | 60 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06439940 | Oncoliq: Early Breast Cancer Detection Based on Liquid Biopsies and microRNAs | unknown | — | 364 | Oncoliq US IncINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06448169 | Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer | unknown | — | 200 | Shandong UniversityOTHER | 0 | Jun 7, 2024 | clinicaltrials |
| NCT06313541 | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy | unknown | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04322578 | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC(CONFIRM) | unknown | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05818449 | Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)(DigiNet) | unknown | N/A | 850 | University of CologneOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06424080 | Oncological and Perioperative Outcomes of Laparoscopic Versus Robotic Partial Nephrectomy for Treatment of Renal Tumors. | unknown | N/A | 20 | Menoufia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06434753 | Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease. | unknown | Phase 3 | 300 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441240 | Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.(NEORISK) | unknown | — | 933 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441357 | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter | unknown | — | 2,000 | Tang-Du HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06442709 | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients | unknown | N/A | 100 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03356236 | Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation | unknown | — | 828 | Yue HanOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT04641819 | Yangzheng Compound Mixture in the Treatment of Sleep Disorder in Cancer Patients | unknown | Phase 4 | 1,127 | ShuGuang HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06436885 | An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer | unknown | Early Phase 1 | 39 | Henan Cancer HospitalOTHER_GOV | 1 | May 31, 2024 | clinicaltrials |
| NCT06436040 | Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | unknown | — | 40 | Tang-Du HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03172416 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis(PIPAC) | unknown | Phase 1 | 21 | National University Hospital, SingaporeOTHER | 2 | May 29, 2024 | clinicaltrials |
| NCT03921671 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)(RELEVENT) | unknown | Phase 2 | 60 | Claudia ProtoOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05395910 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis | unknown | Phase 1 | 36 | National University Hospital, SingaporeOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06429865 | Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma | unknown | N/A | 1,000 | Changhai HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04000906 | PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis(Nab-PIPAC) | unknown | Phase 1 | 18 | University Hospital, GenevaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT05878028 | L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC | unknown | Phase 2 | 33 | Quanli GaoOTHER_GOV | 1 | May 23, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT03724500 | Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer | unknown | — | 65 | Chang Gung Memorial HospitalOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06424821 | Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC(LungCadX) | unknown | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05964101 | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma(GALAXY-1) | unknown | Phase 2 | 25 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06422546 | A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC(pre-FLAME) | unknown | — | 950 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06423144 | PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7 | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 0 | May 21, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2024source: clinicaltrials